While generic drugmakers have yet to be successful in stopping innovators using misusing Risk Evaluation and Mitigation Strategies (REMS) through the legal system, a patient advocate-led class action lawsuit is hoping for better fortunes in what looks to be the first non-manufacturer related complaint on the issue.
The lawsuit – filed June 14 in the US District Court for the District of New Jersey – is being...




